CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Saracatinib +1 moredrug
Likely dose
Saracatinib 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02955186
NCT02955186Phase 2Completed
CompareCT.gov

Fyn Kinase Inhibitors and Alcohol Drinking

Yale University·interventional·Posted Nov 4, 2016·Updated Nov 13, 2020

In Brief

A Phase 2 clinical trial evaluating Saracatinib and Placebos for Alcohol Drinking. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effects of the study medication, saracatinib/AZD0530 (placebo or 125 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. The investigators hypothesize that saracatinib will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Drinking
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 4, 2016
Enrollment StartMay 9, 2017
Primary CompletionApr 24, 2019
Study CompletionJun 7, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.7 years ago

Interventions

Saracatinibdrug

Saracatinib 125 mg once per day for 8 days

Placebosdrug

Placebo once per day for 8 days